Undated
ARCH Venture Partners' Fund 11 is described by host Luke Timmerman as a $1.85 billion fund for investing in new biotech startups.
“Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups.”
Luke Timmerman · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:01:10
Undated
ARCH's Fund 11 press release said it would still write investments ranging from $50,000 to $250 million.
“But you mentioned that you're still going to do these $50 ,000 checks all the way up to $250 million, whatever the thing requires.”
Luke Timmerman · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:06:02
Undated
Luke Timmerman says the Fund 11 press release lists infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic and biological tools, and data sciences among its areas.
“Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.”
Luke Timmerman · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:13:07
Undated
Bob Nelsen contrasts Flagship Pioneering's incubation of companies within Flagship with ARCH's model of incubating companies within existing portfolio companies.
“While Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies.”
Bob Nelsen · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:10:41
Undated
Bob Nelsen says ARCH typically spends about a month trying to reduce the size of a company's financing round to raise the minimum needed from the best investors.
“And almost certainly we spent like a month trying to cut back the size of the round.”
Bob Nelsen · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:39:48
Undated
Bob Nelsen says ARCH has banned the phrase 'news flow' as part of its long-term, science-driven investing culture.
“Yeah, we banned the word news flow from Arch.”
Bob Nelsen · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:42:25
Undated
Xaira Therapeutics was co-founded and incubated by Arch Venture Partners and Foresight Labs.
“Xaira was co-founded and incubated by Arch Venture Partners and Foresight Labs.”
Luke Timmerman · Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI, 0:01:17